Gastrooesophageal cancer+1
Not yet recruitingStudy on the Safety and Effectiveness of Trastuzumab Deruxtecan with Drug Combination for Patients with HER2+ Resectable Esophagogastric Cancer
Study on the Safety and Effectiveness of Trastuzumab Deruxtecan with Drug Combination for Patients with HER2+ Resectable Esophagogastric Cancer
- Disease:Gastrooesophageal cancerHER2 positive gastric cancer
- Substances:FluorouracilOxaliplatin+2
Austria- Participants:18–64 years · 65+ years
- Substances:Fluorouracil
- Sponsor:Institut fuer Klinische Krebsforschung IKF GmbH












